The Numbers Are Getting Ugly

As of the most recent World Health Organization reporting, the DRC Bundibugyo Ebola outbreak stands at 1,041 total cases — 135 confirmed, 906 suspected — with 241 deaths. That's 18 confirmed dead and 223 suspected.

According to the Wall Street Journal, this outbreak has now become the third largest Ebola outbreak in recorded history.

Why This Strain Is Different — And Worse to Fight

The two vaccines that exist for Ebola — Ervebo by Merck and Zabdeno/Mvabea by Johnson & Johnson — do not work against Bundibugyo. Both target the Zaire ebolavirus strain, according to the WHO. The current outbreak is only the third time Bundibugyo has driven a major human outbreak.

There are no licensed vaccines. No approved treatments. Nothing in the global stockpile that applies here.

The Ervebo vaccine, which was 95% effective in trials against Zaire ebolavirus and has been used on over 345,000 people in previous DRC outbreaks according to WHO, is irrelevant to this fight. Most headlines celebrating CEPI's funding announcement omitted this context.

What the CEPI Money Actually Buys

CEPI committed $62 million to develop a Bundibugyo vaccine. The outbreak has kept spreading while that money remains in the preclinical stage.

According to Ars Technica, CEPI committed up to $50 million to Moderna for preclinical development and Phase 1 clinical testing of an mRNA-based Bundibugyo vaccine candidate. The funding also covers manufacturing scale-up and preparation for larger Phase 2/3 trials — if the vaccine passes early testing.

Moderna CEO Stéphane Bancel said in a statement that the company will "move with urgency and scientific rigor." Phase 1 trials test safety in healthy volunteers. Phase 2/3 tests efficacy. That pipeline typically takes years.

The remaining funds go to the International AIDS Vaccine Initiative ($3.2 million, using technology similar to Merck's Ervebo platform) and to Oxford University and the Serum Institute of India ($8.6 million, using an adenovirus platform — the same approach used for Oxford's COVID vaccine), according to Ars Technica.

Why Detection Failed

Detection of this outbreak was delayed, according to Ars Technica. That delay allowed the virus to spread before containment efforts could begin.

The outbreak is spreading in an area of eastern DRC marked by armed conflict, high population movement, and severe humanitarian need. Those conditions make contact tracing and ring vaccination difficult — even if a vaccine were available.

A 2015 NIH-published review in Therapeutic Advances in Vaccines by Saranya Sridhar at Oxford's Jenner Institute documented how the 2014 West Africa outbreak revealed "the lack of a licensed drug or vaccine" and the systemic failure to build a prevention pipeline during non-outbreak periods. A decade later, for a different strain, the same gap exists.

What Mainstream Media Is Getting Wrong

Most coverage — from The Hill to Ars Technica — led with the CEPI-Moderna funding as a win. mRNA platform speed is real. The COVID vaccine development timeline proved that.

Yet framing a Phase 1 investment as a response to an active outbreak with 1,000+ cases credits the global health bureaucracy with solving a problem it has not solved. A vaccine in preclinical development does not help people getting sick right now in eastern DRC.

The Wellcome Trust's historical summary notes it took from 2014 to 2019 for Ervebo to receive full approval — and that was with emergency pressure from the largest Ebola outbreak in history. Moderna's mRNA candidate is earlier in development than Ervebo was in 2014.

The Historical Context Nobody Mentions

The 2014-2016 West Africa outbreak produced over 28,000 suspected cases and 11,000 deaths before a vaccine was deployed, according to Wellcome. The scientific community knew for years that Bundibugyo and Sudan strains lacked vaccine coverage. That was a funding and priority decision.

The NIH review from 2015 listed over 15 different Ebola vaccine candidates in preclinical development at the time. A decade of scientific work later, and Bundibugyo still has ZERO licensed options.

What This Means for Real People

For people in eastern DRC right now, there is no approved medical intervention for Bundibugyo Ebola. They rely on isolation, supportive care, and containment measures — the same tools used in 1976.

The $62 million from CEPI is the right move. Moderna's mRNA platform is genuinely promising. Oxford and Serum Institute have a real track record. But none of that addresses a 2025 outbreak with 2025 cases.

The third largest Ebola outbreak in history is happening in a war zone, with no vaccine, delayed detection, and a global health system releasing press releases. Watch the case count.